Impact of Desensitization on Antiviral Immunity in HLA-Sensitized Kidney Transplant Recipients

Figure 1

The number of CD8+ (a), CD4+ T cells (b), CD19+ B cells (c), and CD56+/CD16+ NK cells (d) pre-DES and posttransplant in 36 DES patients who received DES with IVIg + rituximab followed by a kidney transplant with alemtuzumab induction. Each line with each symbol describes the result from one patient. The results were expressed as the ratio against the pre-DES level in each patient. DES: desensitization; Tx: transplant.

(a) CD8+ T cells

(b) CD4+ T cells

(c) CD19+ B cells

(d) CD56+/CD16+ NK cells